Nasdaq
$0.1500▲ 1.21%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $524,110.65Shares out 3.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
14- 10.16After-hours26.10.17 05:058-KKey event#●●●
VivoSim Labs, INC.
VivoSim Labs' subsidiary, Organovo, has amended its office lease agreement for its San Diego headquarters. The company will reduce its leased space by vacating Suite 202 by February 28, 2027, extend the lease for Suite 100 through April 30, 2028, and adjust the monthly base rent to $43,072.85.…more
$0.1500+1.21%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.6After-hours26.10.07 05:058-KKey event
VivoSim Labs, INC.
VivoSim Labs held its 2026 Annual Meeting on September 30, 2026, where stockholders approved an increase of 3,165,000 shares reserved for the 2022 Equity Incentive Plan. Shareholders also authorized the Board to effect a reverse stock split at a ratio between 1-to-5 and 1-to-20 at any time on or before September 30, 2027. Additionally, the company received approval to issue 4,705,883 shares upon warrant exercise and to reduce the exercise price of May 2024 warrants from $9.60 to $0.85 per share.…more
$0.1500+1.21%vs prev closeView filingShare - 9.1After-hours26.09.02 05:014Ownership
VivoSim Labs, INC.
Insider Lialin Tony Serge of VivoSim Labs reported a change in beneficial ownership of securities effective August 31, 2026. This filing formalizes the insider's equity transaction via SEC Form 4.…more
$0.1500+1.21%vs prev closeView filingShare
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.21 21:05#●●●#●●●#●●●
VivoSim Labs Expands NAMkind Platform with Liver and Intestinal Disease Models…more
VivoSim Labs is extending its NAMkind platform to include efficacy testing services for liver and intestinal disease models. This expansion aims to help drug developers validate candidate efficacy in human tissue before proceeding to clinical trials.…more
$0.1500+1.21%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.7Pre-market26.10.07 21:05
●●●●●●●● ●●●●● ●●●●●●
VivoSim Labs stands to benefit from the FDA's new rule allowing non-animal testing methods for drug safety assessments. However, this announcement reflects a regulatory shift rather than immediate financial results or confirmed revenue growth.…more
$0.1500+1.21%vs prev close - 9.16Pre-market26.09.16 21:05
●●●●●●●● ●●●●● ●●●●●●
VivoSim Labs presented new data from its 3D human liver and intestinal platforms, demonstrating predictive capabilities for drug toxicity in small molecules and ADCs. While the presentation highlights technical progress, it does not include specific commercial contracts or financial performance metrics.…more
$0.1500+1.21%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report